Background: The data comparing the safety and efficacy of second generation drug-eluting stents (DES2) to first generation (DES1) in STEMI patients is limited.
Objective: This study aimed to assess the safety and efficacy of DES2 compared with DES1 (Sirolimus- and Paclitaxel-eluting) in primary PCI.
Methods & Results: The study included 354 consecutive STEMI patients. DS 1 included 150 pts [Cypher 54%, Taxus 46%], and DES 2 included 204 pts [Xience, Promus 39%, Resolute 41%, Biomatrix 20%]. Baseline clinical characteristics were comparable between the two groups.
Between 6m and 2 years three (2.1%) additional events of stent thrombosis occurred in the DES1 group as compared with none (0%) in the DES2 group [p=0.2].
Conclusions: Our preliminary analysis shows that in primary PCI the use of DES2 as compared with DES1 is safe and effective up to two years.
